Araceli Biosciences Closes $11.2M Seed Financing to Change the Pace of Drug Discovery

While advances in automation, genomics, and machine learning have transformed drug discovery, high-content imaging remains one of the slowest steps and a major bottleneck. Traditional imaging systems lack the speed and scalability required for modern AI-driven pipelines and multiplexed assays. Araceli addresses this critical gap with a platform purpose-built for speed, scale, and seamless AI integration—enabling researchers to generate more data, faster, with greater precision. While advances...

While advances in automation, genomics, and machine learning have transformed drug discovery, high-content imaging remains one of the slowest steps and a major bottleneck. Traditional imaging systems lack the speed and scalability required for modern AI-driven pipelines and multiplexed assays. Araceli addresses this critical gap with a platform purpose-built for speed, scale, and seamless AI integration—enabling researchers to generate more data, faster, with greater precision.

Strategic Use of Funds
Proceeds from the Seed round will support:

"The future of AI-driven drug discovery and personalized medicine depends on imaging and analysis that happens in real time," said Matt Beaudet, CEO of Araceli Biosciences. "Minutes and seconds matter. The old model of waiting hours—or even days—for data is over. At Araceli, we're building a platform that moves at the speed of science."

Bill Cortelyou, Board Chairman and lead investor, added, "Araceli's breakthrough technology, experienced leadership, and clear market demand position the company well for significant growth potential."

About Araceli Biosciences
Araceli Biosciences is a biotechnology company focused on accelerating drug discovery through innovations in high-content imaging and AI-driven analysis. With its flagship Endeavor® system and Clairvoyance software, Araceli empowers scientists to generate actionable insights faster and more efficiently across a wide range of biological applications.

Corporate Contact: Shawn MacDonald CFO, Araceli Biosciences
[email protected]
https://www.aracelibio.com/Corporate-Relations

Logo - https://mma.prnewswire.com/media/2672131/Araceli_Biosciences_logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/araceli-biosciences-closes-11-2m-seed-financing-to-change-the-pace-of-drug-discovery-302436895.html